Login Register Cart 0
Generic placeholder image

Letters in Organic Chemistry

Editor-in-Chief

ISSN (Print): 1570-1786
ISSN (Online): 1875-6255

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synthesis of Antipsychotic Drug, Cariprazine: An Improved and Commercially Viable Synthetic Approach

Author(s): Adilakshmi Singavarapu, Gowri Sankar Reddipalli* and Venkat Reddy Ghojala

Volume 19, Issue 1, 2022

Page: [64 - 70] Pages: 7

DOI: 10.2174/1570178618666210921122107

Price: $65

Abstract

The novel synthetic route to the antipsychotic drug Cariprazine was developed and demonstrated on a commercial scale. The synthesis of Cariprazine is achieved from N-(4- oxocyclohexyl) acetamide by using various reactions such as Wittig-Horner reaction, reduction of alkene, hydrolysis of ester, deacylation, amidation, reduction of Weinreb amide to yield the corresponding aldehyde, and finally reductive amination of aldehyde in the presence of the corresponding amine to form Cariprazine. In this article, we report a novel intermediate 2-[trans-4- (3,3-Dimethylureido)cyclohexyl]-N-methoxy-N-methyl acetamide by avoiding potentially genotoxic substances/intermediates, tedious, drastic reaction conditions.

Keywords: Cariprazine, antipsychotic agent, antischizophrenia agent, genotoxic substances, wittig-horner reaction, reductive amination reaction, industrially viable synthetic approach.

« Previous Next »
Graphical Abstract

[1]
Minns, A.B.; Clark, R.F. Toxicology and overdose of atypical antipsychotics. J. Emerg. Med., 2012, 43(5), 906-913.
[http://dx.doi.org/10.1016/j.jemermed.2012.03.002] [PMID: 22555052]
[2]
Leucht, S.; Burkard, T.; Henderson, J.; Maj, M.; Sartorius, N. Physical illness and schizophrenia: A review of the literature. Acta Psychiatr. Scand., 2007, 116(5), 317-333.
[http://dx.doi.org/10.1111/j.1600-0447.2007.01095.x] [PMID: 17919153]
[3]
Fernández, A.; Gómez, C.; Hornero, R.; López-Ibor, J.J. Complexity and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013, 45, 267-276.
[http://dx.doi.org/10.1016/j.pnpbp.2012.03.015] [PMID: 22507763]
[4]
Tasman, A.; Kay, J.; Lieberman, J.A.; First, M.B.; Maj, M. Psychiatry, 3rd ed; Wiley, 2008, pp. 2161-2201.
[http://dx.doi.org/10.1002/9780470515167]
[5]
Carpenter, W.T., Jr; Davis, J.M. Another view of the history of antipsychotic drug discovery and development. Mol. Psychiatry, 2012, 17(12), 1168-1173.
[http://dx.doi.org/10.1038/mp.2012.121] [PMID: 22889923]
[6]
Miyamoto, S.; Miyake, N.; Jarskog, L.F.; Fleischhacker, W.W.; Lieberman, J.A. Mol. Psychiatry, 2012, 17, 1-22.
[http://dx.doi.org/10.1038/mp.2012.47] [PMID: 21483438]
[7]
Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry, 1988, 45(9), 789-796.
[http://dx.doi.org/10.1001/archpsyc.1988.01800330013001] [PMID: 3046553]
[8]
Miyamoto, S.; Duncan, G.E.; Marx, C.E.; Lieberman, J.A. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry, 2005, 10(1), 79-104.
[http://dx.doi.org/10.1038/sj.mp.4001556] [PMID: 15289815]
[9]
Lieberman, J.A.; Stroup, T.S.; McEvoy, J.P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Keefe, R.S.E.; Davis, S.M.; Davis, C.E.; Lebowitz, B.D.; Severe, J.; Hsiao, J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 2005, 353(12), 1209-1223.
[http://dx.doi.org/10.1056/NEJMoa051688] [PMID: 16172203]
[10]
Newcomer, J.W. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs, 2005, 19(Suppl. 1), 1-93.
[http://dx.doi.org/10.2165/00023210-200519001-00001] [PMID: 15998156]
[11]
Haddad, P.M.; Anderson, I.M. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs, 2002, 62(11), 1649-1671.
[http://dx.doi.org/10.2165/00003495-200262110-00006] [PMID: 12109926]
[12]
Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9(15), 641-651.
[http://dx.doi.org/10.1016/S1359-6446(04)03163-0] [PMID: 15279847]
[13]
Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48(21), 6523-6543.
[http://dx.doi.org/10.1021/jm058225d] [PMID: 16220969]
[14]
Morphy, R.; Rankovic, Z. Fragments, network biology and designing multiple ligands. Drug Discov. Today, 2007, 12(3-4), 156-160.
[http://dx.doi.org/10.1016/j.drudis.2006.12.006] [PMID: 17275736]
[15]
Wong, E.H.F.; Tarazi, F.I.; Shahid, M. The effectiveness of multitarget agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action. Pharmacol. Ther., 2010, 126(2), 173-185.
[http://dx.doi.org/10.1016/j.pharmthera.2010.02.001] [PMID: 20171983]
[16]
Csongor, E.A.; Galambos, J.; Nogradi, K.; Vago, I.; Gyertyan, I.; Kiss, B.; Laszlovszky, I.; Laszy, J.; Saghy, K. (Thio) carbamoylcyclohexane derivatives as D3/D2 receptor antagonists. U.S. Pat. Appl. Publ. 20060229297A1, 2006.
[17]
Csongor, E.A.; Galambos, J.; Nogradi, K.; Vago, I.; Gyertyan, I.; Kiss, B.; Laszlovszky, I.; Laszy, J.; Saghy, K. (Thio) carbamoylcyclohexane derivatives as D3/D2 receptor antagonists. U.S. Patent 7,737,142 B2, 2010.
[18]
Csongor, E.A.; Domany, G.; Nogradi, K.; Galambos, J.; Vago, I.; Keseru, G.M.; Greiner, I.; Laszlovszky, I.; Gere, A.; Schmidt, E.; Kiss, B.; Vastag, M.; Tihanyi, K.; Saghy, K.; Laszy, J.; Gyertyan, I.; Zajer-Balazs, M.; Gemesi, L.; Kapas, M.; Szombathelyi, Z. Bioorg. Med. Chem. Lett., 2012, 22, 3437-3440.
[http://dx.doi.org/10.1016/j.bmcl.2012.03.104] [PMID: 22537450]
[19]
Czibula, L.; Juhasz, B.; Csongor, E.A.; Sebok, F.; Galambos, J.; Nogradi, K. Process for the preparation of piperazine compounds and hydrochloride salts thereof. U.S. Patent 8,569,498 B2, 2013.
[20]
Csongor, E.A.; Kirschner, N.A.; Gyertyan, I.; Kiss, B. Metabolites of (thio) carbomoyl-cyclohexane derivatives. U.S. Patent 8,765,765 B2, 2014.
[21]
Veselinović, T.; Paulzen, M.; Gründer, G. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Rev. Neurother., 2013, 13(11), 1141-1159.
[http://dx.doi.org/10.1586/14737175.2013.853448] [PMID: 24175719]
[22]
Kiss, B.; Horváth, A.; Némethy, Z.; Schmidt, E.; Laszlovszky, I.; Bugovics, G.; Fazekas, K.; Hornok, K.; Orosz, S.; Gyertyán, I.; Agai-Csongor, E.; Domány, G.; Tihanyi, K.; Adham, N.; Szombathelyi, Z. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther., 2010, 333(1), 328-340.
[http://dx.doi.org/10.1124/jpet.109.160432] [PMID: 20093397]
[23]
Gyertyán, I.; Kiss, B.; Sághy, K.; Laszy, J.; Szabó, G.; Szabados, T.; Gémesi, L.I.; Pásztor, G.; Zájer-Balázs, M.; Kapás, M.; Csongor, E.A.; Domány, G.; Tihanyi, K. Szombathelyi, Z. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem. Int., 2011, 59(6), 925-935.
[http://dx.doi.org/10.1016/j.neuint.2011.07.002] [PMID: 21767587]
[24]
Xiangchuan, H.; Zhaolun, N.; Genghui, W. CN108586389A, 2018.
[25]
Xiaowen, C.; Kunhua, D.; Jianqi, L.; Feilong, Z. CN104496854A, 2017.
[26]
Min, Z.; Fei, Z. CN110317182A, 2019.
[27]
Gan, L.; Xiang, L.; Deiang, W.; Yabin, W.; Xia, W. CN111004193A, 2020.
[28]
Chen, X.; Liu, F.; Ni, Y.; Fu, L.; Li, J. Synthesis, 2016, 48(18), 3120-3126.
[29]
Chen, X.W.; Sun, Y-Y.; Fu, L.; Li, J-Q. Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3- yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics. Eur. J. Med. Chem., 2016, 123, 332-353.
[http://dx.doi.org/10.1016/j.ejmech.2016.07.038] [PMID: 27487565]
[30]
Flick, A.C.; Ding, H.X.; Leverett, C.A.; Kyne, R.E., Jr; Liu, K.K-C.; Fink, S.J.; O’Donnell, C.J. Synthetic Approaches to the New Drugs Approved During 2015. J. Med. Chem., 2017, 60(15), 6480-6515.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00010] [PMID: 28421763]
[31]
Belliotti, T.R.; Kesten, S.R.; Rubin, J.R.; Wustrow, D.J.; Georgic, L.M.; Zoski, K.T.; Akunne, H.C.; Wise, L.D. Bioorg. Med. Chem. Lett., 1997, 7, 2403-2408.
[http://dx.doi.org/10.1016/S0960-894X(97)00443-5]
[32]
Wustrow, D.; Belliotti, T.; Glase, S.; Kesten, S.R.; Johnson, D.; Colbry, N.; Rubin, R.; Blackburn, A.; Akunne, H.; Corbin, A.; Davis, M.D.; Georgic, L.; Whetzel, S.; Zoski, K.; Heffner, T.; Pugsley, T.; Wise, L. Aminopyrimidines with high affinity for both serotonin and dopamine receptors. J. Med. Chem., 1998, 41(5), 760-771.
[http://dx.doi.org/10.1021/jm9707378] [PMID: 9513604]
[33]
Hendrick, C.E.; Wang, Q. Synthesis of ortho-haloaminoarenes by aryne insertion of nitrogen-halide bonds. J. Org. Chem., 2015, 80(2), 1059-1069.
[http://dx.doi.org/10.1021/jo502541t] [PMID: 25495648]
[34]
Taddei, M.; Cini, E.; Rasparini, M. WO2015056164A1, 2015.
[35]
Lee, C.; Helmy, R.; Strulson, C.; Plewa, J.; Kolodziej, E.; Antonucci, V.; Mao, B.; Welch, C.J.; Ge, Z.; Al-Sayah, M.A. Org. Process Res. Dev., 2010, 14, 1021-1026.
[http://dx.doi.org/10.1021/op1000397]
[36]
Szekely, G.; de Sousa, A. Gil., M.C.; Ferreira, F.C.; Heggie, W. Chem. Rev., 2015, 115(16), 8182-8229.
[http://dx.doi.org/10.1021/cr300095f] [PMID: 26252800]
[37]
Reddy, G. V.; Srinivasulu, R.; Reddy, S. R.; Eswaraiah, S.; Adilakshmi, S.; Rajan, S. T. WO2019/16828A1, 2019.

Rights & Permissions Print Cite
Article Metrics
38
1
© 2024 Bentham Science Publishers | Privacy Policy